Insider Selling: Charles River Laboratories International, Inc. (NYSE:CRL) EVP Sells 1,304 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The sale was disclosed in a filing with the SEC, which is available at this link.

Charles River Laboratories International Price Performance

CRL stock opened at $224.75 on Friday. The stock’s 50 day moving average price is $247.26 and its 200 day moving average price is $227.09. The firm has a market cap of $11.58 billion, a P/E ratio of 26.44, a PEG ratio of 1.80 and a beta of 1.44. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.05 by $0.22. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CRL. Citigroup increased their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. increased their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Robert W. Baird decreased their price objective on shares of Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Argus increased their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a report on Monday, March 18th. Finally, TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $255.27.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds have recently modified their holdings of the company. Meritage Group LP acquired a new position in shares of Charles River Laboratories International in the third quarter valued at approximately $173,174,000. Norges Bank purchased a new stake in Charles River Laboratories International in the 4th quarter worth approximately $101,319,000. Point72 Asset Management L.P. raised its holdings in Charles River Laboratories International by 499.1% in the 4th quarter. Point72 Asset Management L.P. now owns 368,984 shares of the medical research company’s stock valued at $87,228,000 after acquiring an additional 307,398 shares during the last quarter. Rhenman & Partners Asset Management AB purchased a new position in shares of Charles River Laboratories International during the 3rd quarter worth $48,603,000. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of Charles River Laboratories International by 2,733.4% during the first quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock worth $67,060,000 after purchasing an additional 238,766 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).